中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Camu Camu in ART-treated People Living With HIV

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态尚未招聘
赞助商
McGill University Health Centre/Research Institute of the McGill University Health Centre

关键词

抽象

Persons living with HIV and receiving antiretroviral therapy (ART) remain with inflammation leading to higher risks of cardiovascular diseases, fatty liver and cancer. It has been observed in colitis and in HIV infection that abnormal composition of the gut microbes and leaky gut induce inflammation contributing to diabetes, fatty liver and cardiovascular risks. Abundance of Akkermansia muciniphila in stool, a type of good bacteria acting as a shield on the gut barrier has been shown to prevent obesity, diabetes and to improve cancer treatment response. Health food (prebiotic) increases the frequency of A. muciniphila in overweight individuals.
Dr Marette, a study collaborator from Laval University, has recently published (Gut, 2018) that an extract from a Brazilian fruit called Camu Camu (CC) protects mice from obesity, reduce LPS, a marker for passage of microbes from the gut into the blood and decreases inflammation in association with the frequency of A. muciniphila in stools. The extract of CC is sold in nutritional stores to regulate body fat.
The investigators will invite 22 participants to take 2 capsules of CC daily for 12 weeks in addition to their ART. CC tolerance and changes in blood and stools for inflammation and microbe composition will be evalutated at the end of the 12-week treatment and 8 weeks post-intake. An optional sub study will assess the changes of gut barrier by doing biopsies by colonoscopy.
CC is expected to beassociated with an enrichment of A. muciniphila in stools, combined with reduced gut damage and inflammation.

日期

最后验证: 07/31/2019
首次提交: 05/05/2019
提交的预估入学人数: 08/13/2019
首次发布: 08/14/2019
上次提交的更新: 08/13/2019
最近更新发布: 08/14/2019
实际学习开始日期: 08/31/2019
预计主要完成日期: 05/30/2020
预计完成日期: 05/30/2021

状况或疾病

HIV Infections

干预/治疗

Biological: Camu Camu

相 1

手臂组

干预/治疗
Experimental: Camu Camu
Assessments will be done at baseline, during and after 12 weeks of Camu Camu intake.
Biological: Camu Camu
Camu Camu powder encapsulated (500mg each). 2 capsules per day will be used for this study

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

3.2 Inclusion Criteria

Participants will be eligible for the study if they meet the following criteria:

1. Male or female adults ≥18 years of age.

2. Documented HIV-1 infection by Western Blot, Enzyme Immuno Assay (EIA) or viral load assay.

3. On any ART for at least 2 years, with viremia less than 50 copies/ml during the last two years (occasional blips allowed).

4. On a stable ART regimen (same prescription) for at least 3 months.

5. CD4 count >200 and a CD4/CD8 ratio <1 suggesting an increase in inflammation and risk for non-AIDS events.

6. Able to communicate adequately in either French or English.

7. Able and willing to provide written informed consent prior to screening.

8. Women of childbearing potential must have a negative serum pregnancy test.

9. Women of childbearing potential must agree to use one of the following approved methods of birth control while in the study and until 2 weeks after completion:

1. Complete abstinence from penile-vaginal intercourse from the screening period until two weeks after the study completion.

2. Double barrier methods (acceptable barrier methods include diaphragm, coil, contraceptive foam, sponge with spermicide, condom); or

3. Oral, injectable or implant contraceptives plus one barrier method;

4. Intrauterine device (IUD) plus one barrier method; or

5. Male partner sterilization confirmed prior to the female participant's entry into the study; this male is the sole partner for that participant.

6. Approved hormonal contraception, started at least 30 days before screening.

7. Another method approved by the trial physician with published data showing that the expected failure rate is <1% per year preferably with condom.

Any contraception method must be used consistently, in accordance with the approved product label, and for the duration of the study until two weeks after study completion.

10. Women of non-child-bearing potential as defined as either post-menopausal (12 months of spontaneous amenorrhea and ≥ 45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy.

11. Sexually active men with a female partner of childbearing potential must agree to one of the following methods of birth control:

1. The use at least one barrier method of contraception (e.g. condom) with a female partner using a second approved method of contraception (IUD, hormonal contraceptive pill, diaphragm, spermicide etc.) during the study and until two weeks after study completion.

2. Be confirmed sterile.

3. Have had a successful vasectomy.

Exclusion Criteria

Participants are not eligible to participate in the study if they meet any of the following conditions:

1. Known allergy/hypersensitivity to Camu Camu.

2. Current AIDS-related event or serious health condition including systemic infections in the last 3 months.

3. Severe systemic diseases (e.g. uncontrolled hypertension, chronic renal failure), or active uncontrolled infections.

4. Co-infection with active Hepatitis B or C Virus.

5. Current use or have used in the past 3 months: immune-modulatory agents/chemotherapeutics, prophylactic antibiotics35/antibiotics, proton pump inhibitors, phosphate binders, Metformin or Morphine as these drugs can interact with vitamin C or modulate gut microbiota.

6. Diagnosis of diabetes mellitus (HbA1c≥6.5%) as defined by the Canadian Clinical Practice Guidelines for the Prevention and Management of Diabetes42.

7. Frequent use of polyphenol-rich prebiotics (e.g. cranberry and CC powders and/or capsules) in the last 12 months.

8. Statin or other anti-cholesterol treatment use in the last 3 months.

9. Recent changes in dietary habits, intermittent fasting, chronic constipation or laxative use as these can affect gut microbiota.

10. Psychiatric or cognitive disturbance or any illness that could preclude compliance with the study.

11. Current participation in an experimental therapy study or receipt of experimental therapy within the last 6 months.

12. Women who are pregnant, planning to become pregnant, or breast-feeding.

13. A score of higher than 8 on a Full AUDIT questionnaire (See Appendix 1) at the screening visit, suggesting an alcohol abuse problem.

结果

主要结果指标

1. Change in plasma markers of gut epithelial damage (I-FABP) [12 weeks]

2. Changes in plasma microbial translocation marker Lipopolysaccharide (LPS) [12 weeks]

3. Changes in plasma marker of inflammation soluble CD14 (sCD14) [12 weeks]

次要成果指标

1. Incidence of adverse events during and after CC intake in HIV infected participants [20 weeks]

by evaluating adverse events and their intensity (Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events), hematology, and serum chemistries over the course of the study. Evaluations will include: HIV viral load, glucose levels, a lipid profile and plasma levels of hsCRP and D-dimer.

2. Changes in microbiota composition after CC intake [12 weeks]

by 16S rDNA sequencing in stools before and after CC treatment.

3. Changes in HIV reservoir size in blood and gut mucosa [12 weeks]

as assessed by nested qPCR of integrated and total HIV DNA in sorted CD4 T cells from the blood and colon biopsies performed before and after 12 weeks of CC treatment.

4. Difference in baseline gut epithelial marker I-FABP at 2 visits [2 weeks]

Plasma I-FABP levels will be tested at 2 weeks appart before CC treatment to assess intra-participant variability, and ensure changes observed after CC therapy are not due to typical variation between visits.

5. Difference in baseline microbial translocation marker LPS at 2 visits [2 weeks]

Plasma LPS levels will be tested at 2 weeks appart before CC treatment to assess intra-participant variability, and ensure changes observed after CC therapy are not due to typical variation between visits.

6. Difference in baseline inflammation marker sCD14 at 2 visits [2 weeks]

Plasma sCD14 levels will be tested at 2 weeks appart before CC treatment to assess intra-participant variability, and ensure changes observed after CC therapy are not due to typical variation between visits.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge